Patent · US Active

Anti-mesothelin antigen-binding molecules and uses thereof

US11981745B2 · kind B2 · utility

0Cited by

12References

26Claims

0Family size

Inventors

Colin Correnti · Seattle, US
Christopher Mehlin · Seattle, US
David Meininger · Seattle, US
Ashok Bandaranayake · Lake Stevens, US

Key dates

Filing date	Feb 2, 2023
Grant date	May 14, 2024
Priority date	—
Expiry date	Feb 2, 2043

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/94
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure provides antibodies and polypeptides that specifically bind to mesothelin (MSLN), including bispecific antibodies that bind both MSLN and a T cell antigen (e.g., CD3). Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.